SecBot SecBot

FBIOP

Fortress Biotech, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001429260 Biotech & Drug Discovery
Preferred stock of Fortress Biotech, Inc. · FBIO stock page →
$16.45 −0.22 (−1.32%)
Oct 23 4:00 PM ET · prev $16.67
Market cap
$556.0M
Small cap
1 year
+134.3%
from $7.02 · Oct 27
30 days
−0.4%
from $16.52
52-week range
$6.53–21.08
−22% from high · low Nov 13
Avg volume 20D
12.9K
Sep 29 spike 58.8K
Short interest
1.6K
≈0.0% of shares
Days to cover
1.0
at average volume
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 2 reports · latest
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest BULLISH Fortress Biotech reported Q1 2026 net income attributable to common stockholders of $108.4M ($3.44 basic /…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendDOWNTREND

    7% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 8, 2026 Earnings
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an inn
May 14, 2026 SEC
Fortress Biotech reported Q1 2026 net income attributable to common stockholders of $108.4M ($3.44 basic / $2.82…
8-K — Impact 6/10
Mar 31, 2026 SEC
Fortress Biotech reported full-year 2025 financial results, highlighted by a $205 million windfall from the sale of a…
8-K — Impact 8/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$21.6M
Next Q———$22.5M
Current FY———$78.8M
Next FY———$113.3M

Short side

FINRA· Sep 30, 2026
1,600
shares short
1.0
days to cover
≈0.0%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 8, 2026
Earnings
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on…
Jul 27, 2026
Press release
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily…
May 18, 2026
Earnings
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on…
May 14, 2026
Earnings
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare…
May 4, 2026
Earnings
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on…

SecBot reports

2 filings · 2 bullish · 0 bearish
All FBIOP filing & press-release reports (2)